1. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. (12th April 2019) Authors: McInnes, Iain B; Deodhar, Atul; Gladman, Dafna D; Ren, Mengyuan; Spindeldreher, Sebastian; Pricop, Luminita; Porter, Brian; Safi, Jorge; Shete, Abhijit; Bruin, Gerard Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. Issue 2 (7th January 2020) Authors: Bruin, Gerard; Hockey, Hans‐Ulrich P.; La Stella, Phillip; Sigurgeirsson, Bárdur; Fu, Rong; Patekar, Manmath; Charef, Pascal; Woessner, Ralph; Boutouyrie‐Dumont, Bruno Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 2(2020) Page Start: 338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. (3rd April 2022) Authors: Sigurgeirsson, Bardur; Schäkel, Knut; Hong, Chih-Ho; Effendy, Isaak; Placek, Waldemar; Rich, Phoebe; Keefe, Deborah; Bruin, Gerard; Charef, Pascal; Fu, Rong; Hampele, Isabelle; Patekar, Manmath Journal: Journal of dermatological treatment Issue: Volume 33:Number 3(2022) Page Start: 1718 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Low-volume Interscalene Brachial Plexus Block for Perioperative Shoulder Pain. Issue 4 (July 1996) Authors: Bruin, Gerard; McGuire, Glenn Journal: Regional anesthesia Issue: Volume 21:Issue 4(1996) Page Start: 371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis. (8th March 2017) Authors: Bruin, Gerard; Loesche, Christian; Nyirady, Judit; Sander, Oliver Journal: Journal of clinical pharmacology Issue: Volume 57:Number 7(2017) Page Start: 876 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial. Issue 3 (8th January 2022) Authors: Sigurgeirsson, Bardur; Browning, John; Tyring, Stephen; Szepietowski, Jacek C.; Rivera‐Díaz, Raquel; Effendy, Isaak; Keefe, Deborah; Bruin, Gerard; Paguet, Bertrand; Fu, Rong; Hampele, Isabelle; Reinhardt, Maximilian; Patekar, Manmath Journal: Dermatologic therapy Issue: Volume 35:Issue 3(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Issue 2 (23rd November 2015) Authors: Dragatin, Christian; Polus, Florine; Bodenlenz, Manfred; Calonder, Claudio; Aigner, Birgit; Tiffner, Katrin Irene; Mader, Julia Katharina; Ratzer, Maria; Woessner, Ralph; Pieber, Thomas Rudolf; Cheng, Yi; Loesche, Christian; Sinner, Frank; Bruin, Gerard Journal: Experimental dermatology Issue: Volume 25:Issue 2(2016) Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (1st June 2022) Authors: Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. (8th April 2022) Authors: Augustin, Matthias; Reich, Kristian; Yamauchi, Paul; Pinter, Andreas; Bagel, Jerry; Dahale, Swapnil; You, Ruquan; Bruin, Gerard; Djimopoulos, Jimena; Paguet, Bertrand; Charef, Pascal; Patekar, Manmath; Keefe, Deborah Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 942 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis. Issue 6 (3rd August 2019) Authors: Bruin, Gerard; Hasselberg, Anke; Koroleva, Irina; Milojevic, Julie; Calonder, Claudio; Soon, Rachel; Woessner, Ralph; Pariser, David M.; Boutouyrie‐Dumont, Bruno Journal: Clinical pharmacology & therapeutics Issue: Volume 106:Issue 6(2019) Page Start: 1380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗